Amicus in $57M offering to chaperone replacement for enzyme replacement
This article was originally published in Scrip
Rare disease specialist Amicus Therapeutics has raised $57.5 million in a secondary offering through the sale of 10 million shares at a price of $5.70 per share. The shares are being sold at a discount from the $5.96 close on 1 March. The firm expects to receive net proceeds of about $54 million.